Learning Objectives:

  1.       Review current initial therapy for patients with CLL who are <65 years old
  2.        Review the role of ibrutinib in CLL treatment currently
  3.        Discuss the future of ibrutinib as a possible first line therapy for patients <65 years old

Learning Objectives:

  1. Understand the prognostic implication of cell of origin in DLBCL and identify emerging therapies for specific subtypes by cell of origin classification
  2. Define double-expressing lymphoma and its interaction with cell of origin
  3. Understand whom to test for “double-hit” lymphoma and current treatment recommendations
Session date: 
Monday, September 18, 2017 - 12:00pm to 1:00pm
Speaker Name: 
Brian Hess, MD and Michael Leukam, MD
Location: 
University of Chicago Medicine
5841 South Maryland Avenue
MC2115, Conference Room E-215
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.